TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31386273
Drug: Topiramate 125
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 125 mg daily
Study: 28357504
Drug: GAD-alum (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum (two doses)
Study: 28357504
Drug: GAD-alum (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum (four doses)
Study: 25998572
Drug: Extended-release aspirin
Normalized name: aspirin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release aspirin (ER-ASA)
Study: 25998572
Drug: Immediate-release aspirin
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release aspirin (IR-ASA)
Study: 21859401
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (2080 mg daily for 10 weeks)
Study: 18085141
Drug: Ear point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ear point taping and pressing therapy combined with acupoint-injection
Study: 18085141
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine (medication group)
Study: 15181487
Drug: Famciclovir 250
Normalized name: famciclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 250 mg thrice daily
Study: 15181487
Drug: Acyclovir 800
Normalized name: acyclovir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 800 mg 5 times daily
Study: 8083368
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg t.i.d.) during high salt diet
Study: 10095796
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg once daily)
Study: 26944023
Drug: Cenicriviroc (CVC)
Normalized name: salicylic acid
DrugBank: Cenicriviroc (DB11758)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc (CVC) 150 mg
Study: 24913131
Drug: IPL-PDT using
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL-PDT using 0.5% 5-aminolevulinic acid liposomal spray
Study: 15472496
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist
Study: 15472496
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker
Study: 11379373
Drug: Isoflavone-free, isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-free, isocaloric placebo preparation
Study: 8556225
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg twice daily for 12 weeks
Study: 8299854
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg once daily for 12 weeks
Study: 8299854
Drug: Ketanserin plus
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin plus Enalapril (both at original dosage) for 12 weeks
Study: 31852650
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical therapy
Study: 3526267
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (infants weighing less than 750 g at birth)
Study: 28834191
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with fractional CO2 laser and PRP
Study: 28834191
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with fractional CO2 laser and NB-UVB
Study: 20482537
Drug: Uterine artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine artery Doppler test combined with aspirin treatment
Study: 16026136
Drug: Probiotic strain
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic strain Enterococcus faecium M-74 (2x10^9 CFU) plus 50 microg of selenium, administered daily for 56 weeks
Study: 12488294
Drug: Letrozole 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 1.0 mg once daily
Study: 12488294
Drug: Fadrozole 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole 1.0 mg twice daily
Study: 9093891
Drug: Polysulphone low-flux
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysulphone low-flux dialyzers (F6HPS) rinsed with 1000 ml of saline plus 2000 IU of heparin
Study: 9093891
Drug: Polysulphone high-flux
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysulphone high-flux dialyzers (F6OS) rinsed with 1000 ml of saline plus 2000 IU of heparin
Study: 9093891
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups rinsed with 500 ml of saline without heparin
Study: 8425280
Drug: Amiodarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone treatment
Study: 31722605
Drug: Lumpectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumpectomy plus radiotherapy and hormone therapy
Study: 18753076
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol infusion via the common carotid artery (IC group, n=20)
Study: 18753076
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol infusion via the median cubital vein (IV group, n=20)
Study: 7702019
Drug: Nonlactating women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonlactating women and never pregnant women using oral contraceptives
Study: 22001875
Drug: Adjuvanted 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted 2.5 μg RRV vaccine
Study: 22001875
Drug: All vaccine
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccine formulations and doses
Study: 15624747
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream
Study: 15624747
Drug: Adapalene and
Normalized name: Adapalene and Benzoyl Peroxide Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene and tretinoin microsponge gels
Study: 15624747
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream and adapalene creams
Study: 9204091
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel
Study: 15624747
Drug: Vehicle (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (gel vs cream)
Study: 11380642
Drug: Almotriptan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan (various doses 2-150 mg)
Study: 3902590
Drug: Prednisolone 0.5
Normalized name: prednisoLONE 0.5 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 0.5 mg/kg/day plus a normal diet
Study: 3902590
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet plus oral framycetin, colistin and nystatin
Study: 30086036
Drug: Nonoperative Treatment
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonoperative Treatment (NOT)
Study: 27656477
Drug: Intranasal Fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Fluticasone propionate aqueous nasal spray
Study: 24553973
Drug: Oral Montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Montelukast
Study: 17499304
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (sham treated group)
Study: 27416912
Drug: Carfilzomib (10-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (10-min intravenous infusion; 20 mg/m2 on days 1 and 2 of cycle 1; 27 mg/m2 thereafter)
Study: 27416912
Drug: Low-dose corticosteroids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticosteroids (84 mg of dexamethasone or equivalent) with optional cyclophosphamide (1400 mg) for 28-day cycles
Study: 27416912
Drug: Control (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (low-dose corticosteroids with optional cyclophosphamide)
Study: 19241060
Drug: Chronic caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic caffeine administration (400 mg daily for > or =14 days)
Study: 19241060
Drug: Acute caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute caffeine administration
Study: 16838826
Drug: Taper-off program
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper-off program with group therapy
Study: 16838826
Drug: Taper-off program
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper-off program without group therapy
Study: 16838826
Drug: Lower daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower daily benzodiazepine dosage at the start of tapering off
Study: 16838826
Drug: Substantial dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substantial dosage reduction by patients themselves just before tapering off
Study: 12782534
Drug: Magnesium-aluminum-hydroxide-simethicone suspension
Normalized name: aluminum hydroxide / magnesium hydroxide / simethicone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-aluminum-hydroxide-simethicone suspension (MgAl)
Study: 10697140
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of bismuth-based triple therapy (amoxicillin, metronidazole, bismuth subcitrate)
Study: 10697140
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of bismuth-based triple therapy (amoxicillin, metronidazole, bismuth subcitrate)
Study: 9351030
Drug: Omeprazole 60
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 60 mg twice daily plus Amoxicillin 750 mg three times daily for 10 days
Study: 9351030
Drug: Ranitidine prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine prophylaxis 150 mg at night for 2 years
Study: 8224263
Drug: Clonidine (0.300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.300 mg administered orally) once
Study: 8224263
Drug: Growth hormone-releasing
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Growth hormone-releasing factor (GH-RF) (1 micrograms/kg IV) repeated twice
Study: 8224263
Drug: Growth hormone-releasing
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Growth hormone-releasing factor
Study: 22207322
Drug: Iron infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron infusion during HD session
Study: 22207322
Drug: Iron preparations
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparations (iron gluconate, iron sucrose, iron dextran, ferric carboxymaltose)
Study: 22207322
Drug: Culture of
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture of mononuclear cells with iron preparations
Study: 22207322
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of iron sucrose
Study: 20598032
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 microg/6 h)
Study: 18076346
Drug: sapropterin 10
Normalized name: sapropterin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sapropterin 10 mg/kg/day (n = 41)
Study: 9688015
Drug: High-dose albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose albuterol (two 5.0 mg doses administered during 40 minutes)
Study: 9688015
Drug: Standard-dose albuterol
Normalized name: albuterol Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose albuterol (three 2.5 mg doses every 20 minutes)
Study: 9688015
Drug: High-dose albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose albuterol
Study: 2530123
Drug: High-dosage multivitamin
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage multivitamin and mineral supplements
Study: 236108
Drug: Triazolam, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam, 0.4 mg
Study: 236108
Drug: Triazolam, 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam, 0.8 mg
Study: 236108
Drug: Flurazepam, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam, 15 mg
Study: 236108
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active medications
Study: 31981135
Drug: Counselor-administered home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselor-administered home-based testing
Study: 31981135
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to antiretroviral therapy (ART)
Study: 26525144
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy for problem sexual behaviour (MST-PSB)
Study: 21721591
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride topical gel (OTG) 1 g containing oxybutynin chloride 10%, applied once daily to the abdomen, upper arm/shoulder, or thigh.
Study: 21721591
Drug: Post-application showering
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-application showering (1-6 hours after dosing) and sunscreen application (30 minutes before or after OTG application).
Study: 20053323
Drug: Alefacept treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept treatment
Study: 9580803
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous apomorphine infusion
Study: 9580803
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing to apomorphine and its preservative
Study: 3041822
Drug: Uniphyl tablets
Normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uniphyl tablets
Study: 7332913
Drug: Theo-Dur tablets
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theo-Dur tablets
Study: 3041826
Drug: Uniphyl tablets
Normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uniphyl tablets and Theo-Dur tablets
Study: 3041826
Drug: Uniphyl tablet
Normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uniphyl tablet phase
Study: 23736378
Drug: FR-2 appliance
Normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FR-2 appliance treatment for 1.7 years
Study: 23736378
Drug: FR-2 appliance
Normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FR-2 appliance treatment
Study: 15082468
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg/day for 6 weeks
Study: 15082468
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg four times a day for 6 weeks
Study: 15082468
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for Acetaminophen
Study: 12149301
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus 5-FU (600 mg/m(2)/wk) weekly for 3 weeks of every 4 weeks
Study: 12149301
Drug: Gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine alone (1,000 mg/m(2)/wk) weekly for 3 weeks of every 4 weeks
Study: 10460103
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 300 mg under fasting conditions
Study: 10460103
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 300 mg with aluminum-magnesium antacid
Study: 10460103
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 300 mg with a high-fat meal
Study: 8570532
Drug: Cardizem tablets
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardizem tablets
Study: 7130407
Drug: Group condition
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group condition (parent training plus group behavior therapy)
Study: 7130407
Drug: Individual condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual condition (individual family behavior therapy)
Study: 26044148
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone suppositories (400 mg daily starting at 20‐24 weeks of gestation)
Study: 24531792
Drug: 2% ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketamine plus 4% amitriptyline (KA) cream
Study: 23050461
Drug: LaSota vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LaSota vaccine (virus titers ranging from 10(2) to 10(8) EID50 in 10-fold increments)
Study: 23050461
Drug: LaSota vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LaSota vaccine (adequate titer)
Study: 19572933
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg pre-operatively (G2)
Study: 19572933
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg post-operatively (G3)
Study: 10094637
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg in 2 ml of normal saline)
Study: 94637
Drug: Prazosin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (5 mg q.i.d.)
Study: 94637
Drug: Methyldopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500 mg q.i.d.)
Study: 94637
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg twice daily)
Study: 31899371
Drug: Enhanced physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced physical activity monitor (Fitbit wearable activity monitor and mobile app with goal setting and physical activity prescription)
Study: 28457189
Drug: Computerised cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive remediation therapy (CCRT)
Study: 23388155
Drug: MD-GAL (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-GAL (0.9 g MD/kg body mass (BM) per h and 0.3 g GAL/kg BM per h)
Study: 23388155
Drug: MD-GAL-PRO+AA (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-GAL-PRO+AA (0.5 g MD/kg BM per h, 0.3 g GAL/kg BM per h, 0.4 g whey PRO hydrolysate plus l-leucine and l-phenylalanine/kg BM per h)
Study: 21846036
Drug: Vacuum-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-therapy
Study: 21846036
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no vacuum-therapy)
Study: 10454977
Drug: Tirofiban plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban plus heparin and aspirin
Study: 10454977
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and aspirin alone
Study: 7531732
Drug: Cetirizine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (oral tablets) 10 mg twice daily
Study: 399316
Drug: oestriol hemisuccinate
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oestriol hemisuccinate (12 mg/day)
Study: 399316
Drug: oestriol hemisuccinate
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oestriol hemisuccinate (4-6 mg/day)
Study: 9643277
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment
Study: 27443664
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pregabalin capsule (generic product)
Study: 27443664
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pregabalin capsule (reference brand Lyrica)
Study: 23217470
Drug: Conventional gas‐torch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gas‐torch brazing (G-TB)
Study: 10212949
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at 750 mg/day or 1.5 g/day
Study: 1816110
Drug: Aciclovir (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir (1,500 mg/m2/d)
Study: 1816110
Drug: Brivudin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivudin (15 mg/kg/d)
Study: 29849178
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (0.33 to 4.50 g EPA+DHA/day) for 14 days
Study: 29849178
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil supplementation (5.90-6.60 g/d) for 14 days
Study: 22040016
Drug: Parent‐Child Interaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent‐Child Interaction Therapy Emotion Development (PCIT‐ED)
Study: 20582464
Drug: Taxane resistance
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane resistance (TET chemotherapy)
Study: 18048574
Drug: Amlodipine (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (placebo, 5, or 10 mg) and Atorvastatin (placebo, 10, 20, 40, or 80 mg)